COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00140062
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : April 7, 2008
Information provided by:

Brief Summary:
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Condition or disease Intervention/treatment Phase
Ocular Hypertension Glaucoma, Open-Angle Drug: latanoprost 0.005% (Xalatan) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 329 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension
Study Start Date : February 2002
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
Drug Information available for: Latanoprost

Primary Outcome Measures :
  1. Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months.

Secondary Outcome Measures :
  1. Safety and the health care utilization in the two treatment groups over 36 months.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension
  • IOP of > 21 mm Hg on current treatment

Exclusion Criteria:

  • Any previous or current treatment with latanoprost or other prostaglandin analogues

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00140062

Layout table for location information
Pfizer Investigational Site
Helsinki, Finland, 00100
Pfizer Investigational Site
Helsinki, Finland, 00700
Pfizer Investigational Site
Kuopio, Finland, 70100
Pfizer Investigational Site
Lahti, Finland, 15110
Pfizer Investigational Site
Rovaniemi, Finland, 96200
Pfizer Investigational Site
Seinajoki, Finland, 60100
Pfizer Investigational Site
Tammisaari, Finland
Pfizer Investigational Site
Tampere, Finland, 33100
Pfizer Investigational Site
Turku, Finland, 20100
Pfizer Investigational Site
Jönköping, Sweden, 551 85
Pfizer Investigational Site
Karlstad, Sweden, 652 20
Pfizer Investigational Site
Kristianstad, Sweden, 291 31
Pfizer Investigational Site
Linkoping, Sweden
Pfizer Investigational Site
Ludvika, Sweden, 771 81
Pfizer Investigational Site
Molndal, Sweden
Pfizer Investigational Site
Nacka, Sweden, 131 83
Pfizer Investigational Site
Norrkoping, Sweden, 601 82
Pfizer Investigational Site
Norrkoping, Sweden, 602 36
Pfizer Investigational Site
Nyköping, Sweden
Pfizer Investigational Site
Orebro, Sweden, 70361
Pfizer Investigational Site
Seinajoki, Sweden, 151 72
Pfizer Investigational Site
Stockholm, Sweden, 113 22
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
Sundsvall, Sweden, 851 86
Pfizer Investigational Site
Täby, Sweden, 183 34
Pfizer Investigational Site
Uppsala, Sweden, 751 85
Pfizer Investigational Site
Uppsala, Sweden
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information Identifier: NCT00140062    
Other Study ID Numbers: 912-OPT-0091-156
First Posted: August 31, 2005    Key Record Dates
Last Update Posted: April 7, 2008
Last Verified: April 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Antihypertensive Agents